The Magazine for Sleep Professionals
Thursday, July 23, 2026
Boehringer Ingelheim Pharmaceuticals, Inc., donated $500,000 to support the ATS COVID-19 Crisis Fund, a newly launched initiative to develop and disseminate research, education and scientific recommendations to providers in the pulmonary and critical care communities, as well as other clinicians in need of expanding their skill set during this emergency. […]
Once-daily treatment of patients with chronic obstructive pulmonary disease (COPD) with an inhaler combining fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) reduced all-cause mortality by 42 percent, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Reduction in All-Cause Mortality […]
Genentech, a member of the Roche Group announced that the FDA has granted Breakthrough Therapy Designation to Esbriet® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD. The study […]
Teleflex Incorporated has announced a worldwide voluntary recall of the COMFORT FLO® Humidification System. The recalled products provide a continuous flow of heated and humidified gas to COMFORT FLO® patients in professional health care environments. The products involved in the recall are as follows: Product Name Product Code Lot Numbers COMFORT FLO […]
Synspira Therapeutics Inc. has signed an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003, Synspira’s orally delivered non-porcine enzyme replacement therapy (ERT) designed to treat Malabsorption Syndromes. Malabsorption Syndromes are a group of life-threatening disorders that result from defects in the digestion and absorption of macronutrients […]
Merck has announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an update to the prescribing information for BELSOMRA® (suvorexant) C-IV to include findings on its use for the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease. BELSOMRA is indicated for the treatment […]
Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the U.S. Food and Drug Administration (FDA) approved DAYVIGOTM (lemborexant) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized […]
Medical providers must be aware of adverse effects of opioid treatment Patients and medical providers should be aware that chronic opioid use can interfere with sleep by reducing sleep efficiency and increasing the risk of sleep-disordered breathing, according to a position statement from the American Academy of Sleep Medicine. […]
Circassia Pharmaceuticals Inc. announced the launch of DUAKLIR® PRESSAIR® (aclidinium bromide and formoterol fumarate) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).1 DUAKLIR will be available in the United States on October 21st and promoted through its dedicated COPD sales force, alongside established COPD treatment TUDORZA® (aclidinium), which […]
Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha-1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the 29th International Congress of the European Respiratory Society (ERS) in Madrid. ERS is the largest meeting of respiratory professionals in the world and features a scientific and educational programme designed to address […]
